InMode Ltd. (NASDAQ:INMD) Receives $16.80 Consensus Target Price from Analysts

InMode Ltd. (NASDAQ:INMD) has earned an average recommendation of “Hold” from the nine ratings firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $16.80.

Several brokerages have recently weighed in on INMD. BTIG Research reissued a “neutral” rating on shares of InMode in a research report on Monday, January 26th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of InMode in a report on Thursday, January 22nd. Canaccord Genuity Group set a $15.00 price target on shares of InMode and gave the company a “hold” rating in a research note on Wednesday, December 17th. Finally, Robert W. Baird set a $17.00 price objective on shares of InMode in a report on Wednesday, February 11th.

InMode Trading Down 1.9%

Shares of INMD stock opened at $13.53 on Thursday. The company has a market cap of $857.26 million, a P/E ratio of 9.40 and a beta of 2.18. The firm has a fifty day moving average price of $14.26 and a 200 day moving average price of $14.59. InMode has a 12 month low of $12.72 and a 12 month high of $19.09.

InMode (NASDAQ:INMD) last posted its quarterly earnings results on Tuesday, February 10th. The healthcare company reported $0.46 earnings per share for the quarter, beating analysts’ consensus estimates of $0.42 by $0.04. The company had revenue of $103.85 million for the quarter, compared to analysts’ expectations of $104.64 million. InMode had a return on equity of 14.52% and a net margin of 25.33%.InMode’s quarterly revenue was up 6.1% on a year-over-year basis. During the same period last year, the firm earned $0.42 earnings per share. On average, equities analysts forecast that InMode will post 1.75 EPS for the current year.

Institutional Investors Weigh In On InMode

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Leonteq Securities AG purchased a new stake in InMode in the fourth quarter valued at $26,000. Quadrant Capital Group LLC grew its holdings in shares of InMode by 127.8% during the fourth quarter. Quadrant Capital Group LLC now owns 1,945 shares of the healthcare company’s stock worth $29,000 after purchasing an additional 1,091 shares during the last quarter. Advisory Services Network LLC acquired a new stake in shares of InMode during the third quarter worth about $37,000. Basepoint Wealth LLC acquired a new stake in shares of InMode during the fourth quarter worth about $39,000. Finally, Blue Trust Inc. lifted its holdings in shares of InMode by 93.7% in the 3rd quarter. Blue Trust Inc. now owns 2,861 shares of the healthcare company’s stock valued at $43,000 after purchasing an additional 1,384 shares during the last quarter. 68.04% of the stock is currently owned by institutional investors and hedge funds.

About InMode

InMode Ltd. (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.